Quinnox Acquisition

Showing 624 articles
Business

H&R Block: The Bull Case for a Tax Season Titan

Amid market volatility, H&R Block (HRB) presents a compelling value proposition. With aggressive share buybacks, robust cash flow, and strategic expansion beyond tax season, the financial services firm is drawing investor attention for its resilience and shareholder returns.

Business

Gilead Sciences Bets on Precision Oncology to Power Next Growth Phase

Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.